{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:36:23Z","timestamp":1784288183748,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.critrevonc.2025.104949","type":"journal-article","created":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:23:43Z","timestamp":1757859823000},"page":"104949","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Practical tricks and recommendations on BRCA1\/2 testing in prostate cancer: From therapy to cancer prevention"],"prefix":"10.1016","volume":"216","author":[{"given":"Maria Grazia","family":"Tibiletti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ileana","family":"Carnevali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Cimadamore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Oliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Lapini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Genuardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Bracarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4668-4765","authenticated-orcid":false,"given":"Pasquale","family":"Rescigno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104949_bib1","article-title":"Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making","volume":"2017","author":"Abida","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104949_bib2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminoncol.2017.08.004","article-title":"Guidance statement on BRCA1\/2 tumor testing in ovarian cancer patients","volume":"44","author":"Capoluongo","year":"2017","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104949_bib3","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1158\/2159-8290.CD-21-0007","article-title":"Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial","volume":"11","author":"Carreira","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.104949_bib4","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1001\/jama.2018.4914","article-title":"Prostate-specific antigen (PSA) screening for prostate cancer: revisiting the evidence","volume":"319","author":"Carter","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2025.104949_bib5","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer","volume":"37","author":"Castro","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104949_bib6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1158\/1078-0432.CCR-22-0931","article-title":"Detection of BRCA1, BRCA2, and ATM alterations in matched tumor tissue and circulating tumor DNA in patients with prostate cancer screened in PROfound","volume":"29","author":"Chi","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104949_bib7","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00428-023-03660-0","article-title":"SIUrO best practice recommendations to optimize BRCA 1\/2 gene testing from DNA extracted from bone biopsy in mCRPC patients (BRCA Optimal Bone Biopsy Procedure: BOP)","volume":"483","author":"Cimadamore","year":"2023","journal-title":"Virchows Arch."},{"key":"10.1016\/j.critrevonc.2025.104949_bib8","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ejhg.2013.125","article-title":"Recommendations for reporting results of diagnostic genetic testing (biochemical, cytogenetic and molecular genetic)","volume":"22","author":"Claustres","year":"2014","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.critrevonc.2025.104949_bib9","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.6004\/jnccn.2023.0051","article-title":"NCCN Guidelines\u00ae insights: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2024","volume":"21","author":"Daly","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.critrevonc.2025.104949_bib10","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/jnci\/djaa132","article-title":"Germline sequencing DNA repair genes in 5545 men with aggressive and nonaggressive prostate cancer","volume":"113","author":"Darst","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2025.104949_bib11","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104949_bib12","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/humu.23375","article-title":"An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice","volume":"39","author":"Ellison","year":"2018","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.critrevonc.2025.104949_bib13","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/bco2.252","article-title":"Male awareness of prostate cancer risk remains poor in relatives of women with germline variants in DNA-repair genes","volume":"4","author":"Fasulo","year":"2023","journal-title":"BJUI Compass"},{"key":"10.1016\/j.critrevonc.2025.104949_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2022.102164","article-title":"Socioeconomic differences in prostate cancer treatment: a systematic review and meta-analysis","volume":"79","author":"Gallagher","year":"2022","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.critrevonc.2025.104949_bib15","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/clinchem\/hvaa164","article-title":"Generic protocols for the analytical validation of next-generation sequencing-based ctDNA assays: a joint consensus recommendation of the BloodPAC's analytical variables working group","volume":"66","author":"Godsey","year":"2020","journal-title":"Clin. Chem."},{"key":"10.1016\/j.critrevonc.2025.104949_bib16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.critrevonc.2019.05.012","article-title":"Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives","volume":"140","author":"Gori","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104949_bib17","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2016.69.4935","article-title":"Prediction of breast and prostate cancer risks in Male BRCA1 and BRCA2 mutation carriers using polygenic risk scores","volume":"35","author":"Lecarpentier","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104949_bib18","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.21.02112","article-title":"Cancer risks associated with","volume":"40","author":"Li","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104949_bib19","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.clgc.2016.04.016","article-title":"Castration-resistant prostate cancer tissue acquisition from bone metastases for molecular analyses","volume":"14","author":"Lorente","year":"2016","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104949_bib20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","article-title":"Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial","volume":"21","author":"Mateo","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104949_bib21","article-title":"Genomics of lethal prostate cancer at diagnosis and castration-resistance","author":"Mateo","year":"2019","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.critrevonc.2025.104949_bib22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13073-018-0595-5","article-title":"Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis","volume":"10","author":"Mayrhofer","year":"2018","journal-title":"Genome Med."},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104949_bib23","first-page":"00155","article-title":"Combining PARP inhibitors and androgen receptor signalling inhibitors in metastatic prostate cancer: a quantitative synthesis and meta-analysis","volume":"S2588-9311","author":"Messina","year":"2023","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104949_bib24","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO precision medicine working group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104949_bib25","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","article-title":"Prostate cancer risks for Male BRCA1 and BRCA2 mutation carriers: a prospective cohort study","volume":"77","author":"Nyberg","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104949_bib26","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jama.2019.10987","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US preventive services task force recommendation statement","volume":"322","author":"Owens","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2025.104949_bib27","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO precision medicine working group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104949_bib28","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/humu.20880","article-title":"Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results","volume":"29","author":"Plon","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.critrevonc.2025.104949_bib29","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-Repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104949_bib30","first-page":"2371","article-title":"Characterizing CDK12-mutated prostate cancers","author":"Rescigno","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104949_bib31","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"10.1016\/j.critrevonc.2025.104949_bib32","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2025.104949_bib33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-021-01061-x","article-title":"Prostate cancer and PARP inhibitors: progress and challenges","volume":"14","author":"Teyssonneau","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104949_bib34","series-title":"Practice Guidelines for the Evaluation of Pathogenicity and the Reporting of Sequence Variants in Clinical Molecular Genetics","author":"Yvonne Wallis","year":"2019"},{"key":"10.1016\/j.critrevonc.2025.104949_bib35","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1186\/s12885-019-5950-4","article-title":"Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study","volume":"19","author":"Zayas-Villanueva","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2025.104949_bib36","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.prp.2018.05.020","article-title":"Multi-laboratory proficiency testing of clinical cancer genomic profiling by next-generation sequencing","volume":"214","author":"Zhong","year":"2018","journal-title":"Pathol. Res. Pract."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T21:14:50Z","timestamp":1767388490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825003373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":36,"alternative-id":["S1040842825003373"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104949","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical tricks and recommendations on BRCA1\/2 testing in prostate cancer: From therapy to cancer prevention","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104949","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104949"}}